Rigel Pharmaceuticals Stock Forward View - Double Exponential Smoothing
| RIGL Stock | USD 34.32 0.10 0.29% |
Rigel Stock outlook is based on your current time horizon. Although Rigel Pharmaceuticals' naive historical forecasting may sometimes provide an important future outlook for the firm, we suggest always cross-verifying it against solid analysis of Rigel Pharmaceuticals' systematic risk associated with finding meaningful patterns of Rigel Pharmaceuticals fundamentals over time.
As of now the rsi of Rigel Pharmaceuticals' share price is below 20 indicating that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Quarterly Earnings Growth 1.086 | EPS Estimate Next Quarter 0.8 | EPS Estimate Current Year 6.6383 | EPS Estimate Next Year 3.9702 | Wall Street Target Price 51.6 |
Using Rigel Pharmaceuticals hype-based prediction, you can estimate the value of Rigel Pharmaceuticals from the perspective of Rigel Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
Rigel Relative Strength Index
The Double Exponential Smoothing forecasted value of Rigel Pharmaceuticals on the next trading day is expected to be 34.25 with a mean absolute deviation of 1.44 and the sum of the absolute errors of 85.15.Rigel Pharmaceuticals Hype to Price Pattern
Investor biases related to Rigel Pharmaceuticals' public news can be used to forecast risks associated with an investment in Rigel. The trend in average sentiment can be used to explain how an investor holding Rigel can time the market purely based on public headlines and social activities around Rigel Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Rigel Pharmaceuticals' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Rigel Pharmaceuticals.
The Double Exponential Smoothing forecasted value of Rigel Pharmaceuticals on the next trading day is expected to be 34.25 with a mean absolute deviation of 1.44 and the sum of the absolute errors of 85.15. Rigel Pharmaceuticals after-hype prediction price | USD 34.02 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Rigel Pharmaceuticals to cross-verify your projections. Rigel Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Rigel price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Rigel using various technical indicators. When you analyze Rigel charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Rigel Pharmaceuticals Double Exponential Smoothing Price Forecast For the 18th of February 2026
Given 90 days horizon, the Double Exponential Smoothing forecasted value of Rigel Pharmaceuticals on the next trading day is expected to be 34.25 with a mean absolute deviation of 1.44, mean absolute percentage error of 4.48, and the sum of the absolute errors of 85.15.Please note that although there have been many attempts to predict Rigel Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Rigel Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Rigel Pharmaceuticals Stock Forecast Pattern
| Backtest Rigel Pharmaceuticals | Rigel Pharmaceuticals Price Prediction | Research Analysis |
Rigel Pharmaceuticals Forecasted Value
In the context of forecasting Rigel Pharmaceuticals' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Rigel Pharmaceuticals' downside and upside margins for the forecasting period are 30.46 and 38.04, respectively. We have considered Rigel Pharmaceuticals' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Double Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Rigel Pharmaceuticals stock data series using in forecasting. Note that when a statistical model is used to represent Rigel Pharmaceuticals stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.2397 |
| MAD | Mean absolute deviation | 1.4431 |
| MAPE | Mean absolute percentage error | 0.034 |
| SAE | Sum of the absolute errors | 85.1451 |
Predictive Modules for Rigel Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Rigel Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Rigel Pharmaceuticals After-Hype Price Density Analysis
As far as predicting the price of Rigel Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Rigel Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Rigel Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Rigel Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Rigel Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Rigel Pharmaceuticals' historical news coverage. Rigel Pharmaceuticals' after-hype downside and upside margins for the prediction period are 30.23 and 37.81, respectively. We have considered Rigel Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Rigel Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of Rigel Pharmaceuticals is based on 3 months time horizon.
Rigel Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Rigel Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rigel Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Rigel Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.25 | 3.79 | 0.30 | 0.04 | 9 Events / Month | 8 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
34.32 | 34.02 | 0.87 |
|
Rigel Pharmaceuticals Hype Timeline
Rigel Pharmaceuticals is at this time traded for 34.32. The entity has historical hype elasticity of -0.3, and average elasticity to hype of competition of 0.04. Rigel is forecasted to decline in value after the next headline, with the price expected to drop to 34.02. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.87%, whereas the daily expected return is at this time at -0.25%. The volatility of related hype on Rigel Pharmaceuticals is about 2543.62%, with the expected price after the next announcement by competition of 34.36. About 91.0% of the company shares are owned by institutional investors. The company recorded earning per share (EPS) of 6.19. Rigel Pharmaceuticals had not issued any dividends in recent years. The entity had 1:10 split on the 27th of June 2024. Given the investment horizon of 90 days the next forecasted press release will be in about 9 days. Check out Historical Fundamental Analysis of Rigel Pharmaceuticals to cross-verify your projections.Rigel Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Rigel Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Rigel Pharmaceuticals' future price movements. Getting to know how Rigel Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Rigel Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| GOSS | Gossamer Bio | 0.37 | 14 per month | 4.83 | (0.01) | 8.77 | (7.10) | 27.11 | |
| KALV | Kalvista Pharmaceuticals | 0.59 | 9 per month | 3.55 | 0.11 | 8.43 | (6.60) | 25.15 | |
| PRTA | Prothena plc | 0.37 | 10 per month | 0.00 | (0.09) | 5.10 | (4.47) | 14.00 | |
| VTYX | Ventyx Biosciences | 0.06 | 7 per month | 3.21 | 0.11 | 9.00 | (6.33) | 37.04 | |
| FDMT | 4D Molecular Therapeutics | 0.37 | 8 per month | 6.26 | (0.01) | 7.04 | (9.69) | 27.09 | |
| AKBA | Akebia Ther | (0.09) | 9 per month | 0.00 | (0.12) | 5.59 | (6.25) | 20.64 | |
| CRVS | Corvus Pharmaceuticals | (1.16) | 9 per month | 3.10 | 0.11 | 9.63 | (7.20) | 174.42 | |
| OLMA | Olema Pharmaceuticals | 0.15 | 10 per month | 3.03 | 0.13 | 9.82 | (5.86) | 145.73 | |
| BCYC | Bicycle Therapeutics | 0.33 | 7 per month | 0.00 | (0.10) | 6.06 | (5.88) | 14.20 | |
| OMER | Omeros | 0.50 | 11 per month | 4.29 | 0.11 | 12.62 | (7.99) | 87.69 |
Other Forecasting Options for Rigel Pharmaceuticals
For every potential investor in Rigel, whether a beginner or expert, Rigel Pharmaceuticals' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Rigel Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Rigel. Basic forecasting techniques help filter out the noise by identifying Rigel Pharmaceuticals' price trends.Rigel Pharmaceuticals Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rigel Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Rigel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rigel Pharmaceuticals by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Rigel Pharmaceuticals Market Strength Events
Market strength indicators help investors to evaluate how Rigel Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Rigel Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Rigel Pharmaceuticals stock market strength indicators, traders can identify Rigel Pharmaceuticals entry and exit signals to maximize returns.
Rigel Pharmaceuticals Risk Indicators
The analysis of Rigel Pharmaceuticals' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Rigel Pharmaceuticals' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting rigel stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.16 | |||
| Semi Deviation | 4.01 | |||
| Standard Deviation | 4.25 | |||
| Variance | 18.09 | |||
| Downside Variance | 17.13 | |||
| Semi Variance | 16.07 | |||
| Expected Short fall | (3.55) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Rigel Pharmaceuticals
The number of cover stories for Rigel Pharmaceuticals depends on current market conditions and Rigel Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Rigel Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Rigel Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Rigel Pharmaceuticals Short Properties
Rigel Pharmaceuticals' future price predictability will typically decrease when Rigel Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Rigel Pharmaceuticals often depends not only on the future outlook of the potential Rigel Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Rigel Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 17.7 M | |
| Cash And Short Term Investments | 77.3 M |
Check out Historical Fundamental Analysis of Rigel Pharmaceuticals to cross-verify your projections. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. Anticipated expansion of Rigel directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Rigel Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 1.086 | Earnings Share 6.19 | Revenue Per Share | Quarterly Revenue Growth 0.256 | Return On Assets |
Investors evaluate Rigel Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Rigel Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Rigel Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Rigel Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rigel Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Rigel Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.